Alternation in glucagon secretion by Sodium glucose transporter-2 inhibitor

Alternation in glucagon secretion by dietary intake after administration of sodium glucose transporter-2 inhibitor. - Alternation in glucagon secretion by Sodium glucose transporter-2 inhibitor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031190010

Enrollment

Registered

2019-04-16

Start date

2016-05-06

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 diabetes mellitus Type2 deabetes mellitus

Interventions

Administration of sodium glucose transporter-2(SGLT-2) inhibitor, Luseogliflozin, and dose of Luseogliflozin is 25mg once a daily before breakfast, administration period of Luseogliflozin is 12weeks.

D26.255.830

SGLT-2 inhibitor, Luseogliflozin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 (non-insulin dependent) diabetes patients, aged 20 to 79, who are controlled in diet and exercise, and glycated Hb(HbA1c) is 7.0% or above and 10.0% or below.

Exclusion criteria

Exclusion criteria: 1. A patient suffering from acute disease 2. In case of malignacy 3. Renal dysfunction (estimeted GFR 100U/l, ALT >100U/l) 5. Pregnant or possibility of pregnant 6. Lactating mothers 7. A patient suffering from endocrine disorders 8. A patient administrated any drugs affect glucose metabolism 9. Diabetic patients who have taken any hypoglycemic agents include SGLT-2 inhibitor in proximate 6 months 10.A patient undergoing or having history of treatment for ischemic heart disease 11.Chronic heart failure (NYHA class 2 or worse) 12.A patient undergoing or having history of treatment for cerebro-vascular disease 13.A patient undergoing or multiple (3 times or more) history of urinary or genital tract infection 14.A patient accompanied with severe diabetic retinopathy, nephropathy, neuropathy 15.A patient in hyperglycemic crisis or accompanied with marked symptom of hyperglycemia 16.Taking diuretics 17.Correspond to contraindication of Luseogliflozin

Design outcomes

Primary

Measure	Time frame
To elucidate the alternation in glucagon secretion pattern by dietary intake before and after 12 weeks administration of sodium glucose transporter-2(SGLT-2) inhibitor.	—

Secondary

Measure	Time frame
To elucidate the change of the level of plasma glucose, insulin, glucagon related peptide, free fatty acid, and plasma ketone body in glucagon secretion pattern by dietary intake before and after 12 weeks administration of sodium glucose transporter-2(SGLT-2) inhibitor, and relationship between plasma glucagon and these parameters.	—

Contacts

Public ContactRaishi Ichikawa

Kitasato University

raizo@med.kitasato-u.ac.jp+81-427788111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026